Verition Fund Management
XBI icon

Verition Fund Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Verition Fund Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-37,800
Closed -$5.12M – 2355
2021
Q2 		$5.12M Buy
+37,800
New +$4.97M 0.05% 244

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Verition Fund Management's XBI Position: Q1 2026 in Review

Verition Fund Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 46% in Q1 2026, selling an estimated $4.79M and leaving 44,776 shares worth $5.72M. The position accounts for 0.04% of the portfolio, ranked #527.

Verition Fund Management first reported a position in XBI in Q2 2013 and has held it in 22 quarters since. The position peaked at $11.5M in Q2 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Verition Fund Management held 44,776 shares of State Street SPDR S&P Biotech ETF worth $5.72M as of Q1 2026.
  • Verition Fund Management sold 38,400 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $4.79M.
  • State Street SPDR S&P Biotech ETF made up 0.04% of Verition Fund Management's portfolio in Q1 2026, its #527 holding.
  • Verition Fund Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 22 quarters since.
  • Verition Fund Management's State Street SPDR S&P Biotech ETF position peaked at $11.5M in Q2 2025.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.